Literature DB >> 24163474

Comment: Ondansetron: Timing and dosage.

Deepak Hanumanthaiah1, Vinod Sudhir.   

Abstract

Entities:  

Year:  2013        PMID: 24163474      PMCID: PMC3800352          DOI: 10.4103/0019-5049.118527

Source DB:  PubMed          Journal:  Indian J Anaesth        ISSN: 0019-5049


× No keyword cloud information.
Sir, We read with interest an article titled “comparative electrocardiographic effects of intravenous ondansetron and granisetron in patients undergoing surgery for carcinoma breast: A prospective single-blind randomized trial.”[1] In the article the authors divided patient post-surgery into 2 groups randomly. One of them received ondansetron 8 mg and the other granisteron 1 mg intravenously. We feel the study was flawed in two ways: The timing of anti-emetics: Most of the literature would suggest giving anti-emetics either at the start of surgery[2] or 30 min before the end of surgery for prevention of post-operative nausea and vomiting (PONV).[3] After PONV has started in recovery period even doses of 1 mg intravenously is shown to be as beneficial as 8 mg intravenously with no difference in either patient outcome or satisfaction.[4] So giving all patient ondansetron or granisetron in recovery only to see for QT prolongation seems to be flawed. It is not mentioned in the article about whether the patient felt nauseated or vomited in the recovery. Studies have shown that if a postoperative patient vomits after getting 4 mg of prophylactic ondansetron in the recovery room, an additional 4 mg treatment dose of ondansetron is not better than a placebo to control the vomiting,[5] so giving a standard dose to all patients may distort the study. Zofran (trade name) which is manufactured by GlaxoSmithKline recommends in its website that the dose for PONV should be 4 mg intravenously. The authors have also not specified if the anti-emetics were given for prophylaxis or treatment. The Food and Drug Administration (FDA) in 2011 has issued a statement stating that by using ondansetron, QT prolongation occurs in a dose-dependent manner.[6] So, in view of this recommendation by FDA, which is accepted and followed worldwide, using ondansteron to demonstrate QT prolongation is unethical in our view as it is an accepted complication especially when generalizing 8 mg as a standard dose irrespective of weight.
  5 in total

1.  Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials.

Authors:  M R Tramèr; D J Reynolds; R A Moore; H J McQuay
Journal:  Anesthesiology       Date:  1997-12       Impact factor: 7.892

2.  The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting.

Authors:  J Tang; B Wang; P F White; M F Watcha; J Qi; R H Wender
Journal:  Anesth Analg       Date:  1998-02       Impact factor: 5.108

3.  Efficacy of repeat intravenous dosing of ondansetron in controlling postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled multicenter trial.

Authors:  A L Kovac; T A O'Connor; M H Pearman; L J Kekoler; D Edmondson; V L Baughman; J J Angel; C Campbell; H G Jense; M Mingus; M B Shahvari; M R Creed
Journal:  J Clin Anesth       Date:  1999-09       Impact factor: 9.452

4.  Antiemetic prophylaxis does not improve outcomes after outpatient surgery when compared to symptomatic treatment.

Authors:  P E Scuderi; R L James; L Harris; G R Mims
Journal:  Anesthesiology       Date:  1999-02       Impact factor: 7.892

5.  Comparative electrocardiographic effects of intravenous ondansetron and granisetron in patients undergoing surgery for carcinoma breast: A prospective single-blind randomised trial.

Authors:  Ashish Ganjare; Atul P Kulkarni
Journal:  Indian J Anaesth       Date:  2013-01
  5 in total
  2 in total

1.  A comparative study of effects of glycopyrrolate and ondansetron on nausea and vomiting in cesarean section under spinal anesthesia.

Authors:  Ragi Jain; Rashmi Sharma
Journal:  Anesth Essays Res       Date:  2015 Sep-Dec

2.  Response: Comparative electrocardiographic effects of intravenous ondansetron and granisetron in patients undergoing surgery for carcinoma breast: A prospective single blind randomised trial.

Authors:  Ashish Ganjare; Atul P Kulkarmi
Journal:  Indian J Anaesth       Date:  2013-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.